-+ 0.00%
-+ 0.00%
-+ 0.00%
Is Pfizer (PFE) Undervalued On Its $1.5b Berobenatide Funding Deal?
Share
Listen to the news

Pfizer (PFE) just secured up to US$1.5b in external funding from Blackstone Life Sciences for berobenatide, its investigational monthly GLP 1 obesity drug, while keeping full ownership and control of the program.

Pfizer’s latest move on berobenatide comes after a busy stretch that includes higher 2026 revenue guidance, the appointment of CFO Cecile Guegan, and fresh legal actions around COVID 19 vaccine technology. The share price is up 14.73% year to date and the total shareholder return over one year is 23.00%, indicating that momentum has picked up compared with the weaker five-year total shareholder return, which is down 25.48%.

Scan how Pfizer’s obesity push compares with other pharma players leaning into similar themes by reviewing our hand picked list of 38 healthcare AI stocks in one place.

Pfizer now has fresh capital support for berobenatide, a higher share price and a still stretched payout. Does that mix still offer an attractive trade off for new buyers at today’s valuation?

Most Popular Narrative: 3% Undervalued

Pfizer last closed at $28.89, compared with the analyst consensus Narrative fair value of $29.72 from Simply Wall St, which uses analyst earnings and revenue forecasts and a 7.24% discount rate to frame the long term risk and reward.

Expansion of launched and acquired products, which management now describes as running at around a US$13b annualized revenue rate and growing in the 20% range, continues to support the view that Pfizer can further shift its mix toward non COVID therapies and sustain revenue as loss of exclusivity pressures emerge. Execution on large scale productivity and manufacturing programs, now expected to deliver about US$9.7b in net savings through 2029 after already removing US$7.2b from the cost base, provides a longer runway for operating margin support and underpins earnings capacity while Pfizer increases R&D spending on oncology and obesity.

See why 567 investors see Pfizer as 3% undervalued.

Result: Fair Value of $29.72 (UNDERVALUED)

Still, the narrative for Pfizer can be knocked off course if drug pricing reforms bite harder than expected, or if key pipeline assets fail to deliver on current analyst assumptions.

Find out about the key risks to this Pfizer narrative.

Next Steps

Mixed signals around value and risk can make Pfizer tricky to pin down, so move quickly, review the evidence, and weigh both sides through the 2 key rewards and 4 important warning signs.

Looking for more investment ideas beyond Pfizer?

If Pfizer sits on your watchlist, do not stop there. A broader bench of quality opportunities can steady your portfolio and sharpen your decision making.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending